Pieris Pharmaceuticals (NASDAQ:PIRS) Stock Rating Upgraded by StockNews.com

Pieris Pharmaceuticals (NASDAQ:PIRS) was upgraded by stock analysts at StockNews.com from a “sell” rating to a “hold” rating in a report issued on Tuesday.

Pieris Pharmaceuticals Stock Performance

NASDAQ:PIRS opened at $16.01 on Tuesday. Pieris Pharmaceuticals has a one year low of $6.20 and a one year high of $22.32. The stock has a market cap of $21.13 million, a PE ratio of -1.32 and a beta of 0.66. The stock has a 50 day moving average price of $16.54 and a 200 day moving average price of $13.85.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pieris Pharmaceuticals stock. Frazier Life Sciences Management L.P. purchased a new stake in Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 15,942 shares of the biotechnology company’s stock, valued at approximately $267,000. Frazier Life Sciences Management L.P. owned 1.21% of Pieris Pharmaceuticals at the end of the most recent reporting period. Institutional investors and hedge funds own 40.11% of the company’s stock.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.